RUXSAC -A double blind, placebo-controlled, randomized phase II study of Pemetrexed and Cisplatin with and without Ruxolitinib in Malignant Pleural Mesothelioma.

Project Details

Short titleRUXSAC -A double blind, placebo-controlled, randomized phase II study of Pemetrexed and Cisplatin with and without Ruxolitinib in Malignant Pleural Mesothelioma.
StatusFinished
Effective start/end date17/12/15 → 31/12/20

Funding

  • NIHR
  • NOVARTIS PHARMACEUTICALS UK LTD